Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 135460
Corporate User License Price USD 6000
Corporate User License Price INR 406380
Site License Price USD 4000
Site License Price INR 270920
Request a Quote

Report Title

Herpes Zoster (Shingles)-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Herpes Zoster (Shingles)-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Herpes Zoster (Shingles)-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Herpes Zoster (Shingles)-Pipeline Review, H1 2017



Executive Summary

Herpes Zoster (Shingles)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles)-Pipeline Review, H1 2017, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.

Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 3, 1, 1, 6 and 1 respectively.

Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Herpes Zoster (Shingles)-Overview

Herpes Zoster (Shingles)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Herpes Zoster (Shingles)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Herpes Zoster (Shingles)-Companies Involved in Therapeutics Development

Astellas Pharma Inc

Beijing Minhai Biotechnology Co Ltd

ContraVir Pharmaceuticals Inc

Epiphany Biosciences Inc

Foamix Pharmaceuticals Ltd

GeneOne Life Science Inc

GlaxoSmithKline Plc

Merck & Co Inc

NAL Pharmaceuticals Ltd

NanoViricides Inc

SK Chemicals Co Ltd

TSRL Inc

XBiotech Inc

Herpes Zoster (Shingles)-Drug Profiles

acyclovir-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amenamevir-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FV-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLS-5100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-1437173A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes zoster vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Shingles-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAL-3223-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NBP-608-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Shingles-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TSR-087-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

V-212-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

valomaciclovir stearate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Herpes Zoster (Shingles)-Dormant Projects

Herpes Zoster (Shingles)-Discontinued Products

Herpes Zoster (Shingles)-Product Development Milestones

Featured News & Press Releases

Apr 18, 2017: GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles

Feb 24, 2017: In First Phase 3 Trial, Merck's Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects

Nov 25, 2016: GSK announces EU regulatory submission of candidate vaccine for prevention of shingles-Follows regulatory submissions in US and Canada

Oct 27, 2016: GSK presents new data for shingles candidate vaccine at IDWeek scientific conference

Oct 24, 2016: GSK announces US regulatory submission of candidate vaccine for prevention of shingles

Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM

Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles

Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug

Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study

Oct 27, 2015: GSK's candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over

Sep 08, 2015: Clinical trial for Cardiff's shingles treatment

Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain

Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial

Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied

Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Herpes Zoster (Shingles), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Herpes Zoster (Shingles), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Herpes Zoster (Shingles)-Pipeline by Astellas Pharma Inc, H1 2017

Herpes Zoster (Shingles)-Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017

Herpes Zoster (Shingles)-Pipeline by ContraVir Pharmaceuticals Inc, H1 2017

Herpes Zoster (Shingles)-Pipeline by Epiphany Biosciences Inc, H1 2017

Herpes Zoster (Shingles)-Pipeline by Foamix Pharmaceuticals Ltd, H1 2017

Herpes Zoster (Shingles)-Pipeline by GeneOne Life Science Inc, H1 2017

Herpes Zoster (Shingles)-Pipeline by GlaxoSmithKline Plc, H1 2017

Herpes Zoster (Shingles)-Pipeline by Merck & Co Inc, H1 2017

Herpes Zoster (Shingles)-Pipeline by NAL Pharmaceuticals Ltd, H1 2017

Herpes Zoster (Shingles)-Pipeline by NanoViricides Inc, H1 2017

Herpes Zoster (Shingles)-Pipeline by SK Chemicals Co Ltd, H1 2017

Herpes Zoster (Shingles)-Pipeline by TSRL Inc, H1 2017

Herpes Zoster (Shingles)-Pipeline by XBiotech Inc, H1 2017

Herpes Zoster (Shingles)-Dormant Projects, H1 2017

Herpes Zoster (Shingles)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Astellas Pharma Inc, Beijing Minhai Biotechnology Co Ltd, ContraVir Pharmaceuticals Inc, Epiphany Biosciences Inc, Foamix Pharmaceuticals Ltd, GeneOne Life Science Inc, GlaxoSmithKline Plc, Merck & Co Inc, NAL Pharmaceuticals Ltd, NanoViricides Inc, SK Chemicals Co Ltd, TSRL Inc, XBiotech Inc


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand